Mounjaro Dosing: What the Titration Schedule Actually Means

The myth that every patient climbs to 15mg on schedule

A question our prescribers hear most weeks: "So I'll be on the highest dose by month six?" The short answer is: not necessarily, and that's not the goal. The 2.5mg starting dose exists because tirzepatide causes gastrointestinal effects (nausea, loose stools, reflux) that are significantly more manageable when the body acclimates gradually. Think of the first pen as your system finding its footing, not as treatment being withheld.

The titration schedule in the Mounjaro SmPC is a minimum-four-weeks-per-step structure: 2.5mg for at least four weeks, then 5mg for at least four weeks, and so on. "At least" is the operative phrase. Many people stay at 5mg or 7.5mg for longer because they're losing weight comfortably and tolerating that dose well. Pushing to 15mg when 7.5mg is working is not the aim. The prescriber's role is to find the lowest effective dose, not the highest tolerated one. That distinction matters more than most patients realise at the start.

NICE's appraisal of tirzepatide (TA1026) notes that if someone loses less than 5% of their body weight after six months at the highest tolerated dose, the decision to continue should be reviewed. This reinforces that dose increases serve a clinical purpose, not a commercial one.

What actually happens at each step

The six strengths map onto a straightforward sequence. Each KwikPen contains four doses, so one pen covers one month. At 2.5mg, most people notice little change in appetite; the early weeks are about stomach adjustment. By 5mg, appetite suppression (the dual GIP and GLP-1 receptor activation slowing gastric emptying and signalling fullness) typically becomes noticeable. The tirzepatide overview explains the mechanism in more detail if that's useful context.

After 5mg the path forks depending on the individual. Some move through 7.5, 10 and 12.5mg in relatively steady four-week increments. Others plateau at a mid-range dose for months. A minority reach 15mg; some never go beyond 10mg because it does the job. Side effects at any step (persistent nausea, significant vomiting, inability to eat) are grounds for the prescriber to hold the current dose or step back down. That's not failure; that's the schedule doing what it was designed to do.

If you want a visual layout of the six steps alongside their timing, the Mounjaro dosing chart sets it out clearly.

Variations that sometimes cause confusion

Patients transferring from another provider, those who have had a treatment break of more than a week or two, and those considering a change to their injection day all face slightly different guidance. None of these scenarios should be self-managed. The same applies to short-dosing questions, where patients wonder whether a partial injection is appropriate when side effects are sharp, it isn't a licensed approach and raises supply and safety issues that a prescriber needs to assess.

There is also a growing amount of online discussion around micro-dosing and split-dosing approaches. These are not part of the licensed titration schedule and are not something a responsible prescriber would recommend outside a controlled clinical context. The licensed schedule exists because it was developed through trials involving thousands of adults (SURMOUNT-1 alone enrolled 2,539 participants) and the step increments reflect real tolerability data, not guesswork.

Pricing also feeds into these conversations. Since Eli Lilly adjusted UK list prices in autumn 2025 (background on that here) some patients have asked whether staying at a lower dose longer saves money. That logic is understandable, but clinical decisions shouldn't be shaped by cost alone. If you're weighing what private treatment involves, the weight-loss treatments overview sets out what to look for in a provider.

How dose decisions work at nume

Every dose increase at nume requires clinical review, not an automatic progression triggered by a calendar. When a repeat is due, a prescriber checks your responses, any side-effect history, and whether the current dose is doing its job. Dose increases also require evidence of progress and tolerability before a higher-strength pen is approved. This happens before every supply, every time. There are no subscriptions and no auto-renewals; each order is a fresh clinical decision.

If you're thinking about starting treatment or have questions about where you'd fit in the titration schedule, the best next step is a proper clinical conversation. Start your free consultation and a GPhC-registered prescriber will review your answers the same day. Our clinical team is here to make sure your dosing plan is right for you, not just convenient.